Critical care of the hematopoietic stem cell transplant recipient

Critical Care Clinics
Bekele Afessa, Elie Azoulay

Abstract

An estimated 50,000 to 60,000 patients undergo hematopoietic stem cell transplantation (HSCT) worldwide annually, of which 15.7% are admitted to the intensive care unit (ICU). The most common reason for ICU admission is respiratory failure and almost all develop single or multiorgan failure. Most HSCT recipients admitted to ICU receive invasive mechanical ventilation (MV). The overall short-term mortality rate of HSCT recipients admitted to ICU is 65%, and 86.4% for those receiving MV. Patient outcome has improved over time. Poor prognostic indicators include advanced age, poor functional status, active disease at transplant, allogeneic transplant, the severity of acute illness, and the development of multiorgan failure. ICU resource limitations often lead to triage decisions for admission. For HSCT recipients, the authors recommend (1) ICU admission for full support during their pre-engraftment period and when there is no evidence of disease recurrence; (2) no ICU admission for patients who refuse it and those who are bedridden with disease recurrence and without treatment options except palliation; (3) a trial ICU admission for patients with unknown status of disease recurrence with available treatment options.

References

Mar 1, 1992·The American Review of Respiratory Disease·S W Crawford, F B Petersen
Jan 1, 1989·Critical Care Medicine·S J DenardoP E Bellamy
Jan 1, 1988·Intensive Care Medicine·C TorrecillaE Dominguez de Villota
Oct 1, 1985·Critical Care Medicine·W A KnausJ E Zimmerman
Nov 24, 1993·JAMA : the Journal of the American Medical Association·S LemeshowJ Rapoport
Sep 18, 1996·JAMA : the Journal of the American Medical Association·A F ConnorsW A Knaus
Sep 10, 1998·American Journal of Respiratory and Critical Care Medicine·K J PriceB S Andersson
Dec 10, 1999·American Journal of Respiratory and Critical Care Medicine·J P KressJ B Hall
May 16, 2000·Critical Care Medicine·A J HuaringaR E Champlin
Mar 10, 2001·The New England Journal of Medicine·G R BernardUNKNOWN Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group
May 1, 2001·British Journal of Haematology·M F MurphyUNKNOWN British Committee for Standards in Haematology, Blood Transfusion Task Force
Jun 5, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E NininH Richet
Jan 17, 2002·The New England Journal of Medicine·E RiversUNKNOWN Early Goal-Directed Therapy Collaborative Group
Feb 13, 2002·Bone Marrow Transplantation·L F Bleggi-TorresC R de Medeiros
Aug 21, 2002·JAMA : the Journal of the American Medical Association·Djillali AnnaneEric Bellissant
Sep 3, 2002·American Journal of Respiratory and Critical Care Medicine·Bekele AfessaSteve G Peters
Oct 31, 2002·American Journal of Respiratory and Critical Care Medicine·Bekele AfessaSteve G Peters
Nov 30, 2004·British Journal of Haematology·M Bishton, R Chopra
Jul 5, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guillaume ThiéryBenoît Schlemmer
Nov 3, 2005·Clinics in Chest Medicine·Steve G Peters, Bekele Afessa
Nov 26, 2005·Intensive Care Medicine·Elie Azoulay, Bekele Afessa
Dec 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frédéric PèneJean-Paul Mira
Feb 3, 2006·The New England Journal of Medicine·Greet Van den BergheRoger Bouillon
Mar 1, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Andrea K KewDarrell White

❮ Previous
Next ❯

Citations

Sep 13, 2011·Annals of Intensive Care·Elie AzoulayBekele Afessa
Sep 24, 2013·Bone Marrow Transplantation·R BenzG Stussi
Jan 22, 2014·Critical Care : the Official Journal of the Critical Care Forum·Philipp WohlfarthUNKNOWN Arbeitsgruppe für hämato-onkologische Intensivmedizin der Österreichischen Gesellschaft für Internistische und Allgemeine In
Nov 26, 2013·Best Practice & Research. Clinical Anaesthesiology·Timothy James WigmoreAndrew Lawson
Apr 6, 2012·The American Journal of the Medical Sciences·Wen-Chi YangPo-Nan Wang
Dec 18, 2013·Journal of Critical Care·Ayman O SoubaniDaryn Smith
Jul 9, 2013·Critical Care Clinics·Eric J Bow
Aug 5, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Patricia JenkinsD Kathryn Tierney
Aug 21, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Karen EscobarPablo Ramirez
May 23, 2015·Blood Reviews·Elie AzoulayUNKNOWN Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique (Grrr-OH)
Jan 20, 2015·Critical Care Medicine·Gagan KumarUNKNOWN Milwaukee Initiative in Critical Care Outcomes Research Group of Investigators
Aug 20, 2015·British Journal of Haematology·Matt P WiseUNKNOWN British Committee for Standards in Haematology
Mar 24, 2015·Bone Marrow Transplantation·E LenglinéE Azoulay
Oct 3, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Christopher GilbertMichael Baram
May 29, 2014·Clinical Journal of Oncology Nursing·Kelli Thoele
Oct 16, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ulas D BayraktarJoseph L Nates
Apr 15, 2017·Critical Care Medicine·Philipp WohlfarthUNKNOWN Caring for Critically Ill Immunocompromised Patients Multinational Network (NINE-I)
Jan 14, 2016·Revista da Escola de Enfermagem da U S P·Juliana Bastoni da SilvaSílvia Regina Secoli
Jun 29, 2017·European Journal of Haematology·Astrid M P DemandtWalther N K A van Mook
Nov 7, 2019·Journal of the Intensive Care Society·Leila TaheriVictoria Metaxa
Aug 24, 2019·Journal of Critical Care·Perrine LeprêtreDéborah Boyer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.